The Expert Angle
Medlior is a well-known and trusted industry leader.
Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.
Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.
Real-World Evidence in Health Technology Assessments
The Use of Real-World Evidence in Health Technology Assessments by the Canadian Agency for Drugs and Technologies in Health
Increasingly real-world data (RWD) are being used to inform decision-making in health technology assessments (HTAs) by providing information (real-world evidence, or ...
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status
Gene therapy is a growing area of interest for the treatment of several diseases. These therapies are intended to offer a one-time treatment to modify a person’s genes through a ...
Insights from the Women in Data Science Event
On March 4th, 2019, Medlior attended the regional Women in Data Science event, hosted by the Cumming School of Medicine at the University of Calgary. Women in Data Science (WiDS) is an internationally-broadcasted event hosted at Stanford University and has spurred many regional events since ...
CAR-T Therapy: Challenges for Implementation in Canada
CAR-T Therapy: Challenges for Implementation in Canada
In 2017, autologous chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel (Kymriah®, Novartis), became the first gene therapy approved in the United States for acute lymphoblastic leukemia in children and young adults. In 2018, ...
Canadian Provincial Administrative Health Data for Research: It’s Better in Alberta
Alberta’s administrative health system data covers 4.2 million residents and includes pharmacy-level drug claims data and province-wide laboratory data. Community researchers, such as Medlior, have direct access to de-identified health system data in Alberta for ethics-approved industry-sponsored research.
Bell Let’s Talk Day and the potential to close existing patient data gaps
Bell Let’s Talk Day is an amazing initiative that is helping to end the stigma of mental health as well as raise fund for research initiatives. Here’s how programs like this can help bridge the current data gap that exists in the mental health sector. #BellLetsTalk
Identifying the prevalence and characteristics of patients with migraines
For patients with migraines, it is more than just a headache. As new therapies enter the market, improvements may be seen in medication adherence with a subsequent improvement in the burden of disease, healthcare utilization and costs.
Medlior predictions for 2019 in the world of health outcomes research
After tremendous growth and success in 2018, Medlior is looking forward to tackling 2019 with a mindset of innovation and enthusiasm!
One of the reasons our team loves working at Medlior is our core purpose of positively impacting global health through rigorous research, and we look forward to contributing more towards our goal this year.
Our work within the healthcare industry offers us a unique perspective on upcoming initiatives and trends and we’ve put together 6 predictions we think you will see in 2019.
Medlior insights from 2018 in the world of health outcomes research
Medlior’s Top Insights from 2018
Looking back at 2018 through the world of health outcomes research.
2018 has been a fantastic year, we’ve seen some amazing biotech innovations and breakthroughs in many areas of clinical research. The Medlior team is interested to see how these advancements ...
Canadian Drug Coverage: Understanding Canadian Drug Coverage
Understanding Canadian Insurance Coverage and the discrepancy in current data
The proportions of public and private prescription drug coverage vary substantially between provinces in Canada. Variations in prescription drug coverage in different provinces can likely be attributed to ...
RWE for Providers
Medlior-RWE-for-Prviders
RWE For Patients
Medlior-RWR-for-Patients